|
|
|
20.10.25 - 14:06
|
Moderna Aktie: Hoffnungsschimmer in der Krebsforschung - doch die Risiken bleiben gewaltig (Aktiencheck)
|
|
|
New York (www.aktiencheck.de) - Moderna-Aktienanalyse von Wolfe Research:
Die Analystin Alexandria Hammond von Wolfe Research habe erklärt, dass Moderna (ISIN: US60770K1079, WKN: A2N9D9, Ticker-Symbol: 0QF, NASDAQ-Symbol: MRNA) auf dem ESMO 2025 einen Investoren-Webcast abgehalten habe, um neue Daten aus seiner Phase-1/2-Studie zu mRNA-4359 sowie zur allgemeinen Krebs-Pipeline des Unternehmens vorzustellen. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
09.10.25 - 13:06
|
Biopharma Leaders Advance the Future of Life Sciences at Veeva Commercial Summit Europe (PR Newswire)
|
|
|
Industry gathers to explore Veeva AI innovations and exchange ideas with companies including Astellas, Bayer AG, Boehringer Ingelheim, LEO Pharma, Moderna, and MSD BARCELONA, Spain, Oct. 9, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Astellas, Bayer AG, Boehringer......
|
|
|
08.10.25 - 09:03
|
Clustermarket Rebrands to Calira and Secures Industry Veteran to Capitalise on Demand for Optimised R&D Lab Operations (Business Wire)
|
|
|
Lab equipment scheduling platform supporting pharma and life sciences R&D organisations' AI journey amidst industry upheavalLONDON--(BUSINESS WIRE)--Clustermarket, the lab equipment scheduling platform, has today announced it is rebranding to Calira and welcoming non-executive director and investor Edmund Wilson, co-founder and former CEO of Titian Software (now Cenevo), to capitalise on increasing enterprise demand for optimising lab operations.
The company's software has been popular with academic institutions and SMBs for several years, but has seen a recent upsurge in interest from enterprise research and development organisations—such as Merck (MSD), Moderna, Eli Lilly, Takeda and Lonza—as pharma and life sciences companies navigate market turmoil. This follows wider industry data that shows global biopharma lay-offs rose 63% in 2024 compared to 2022.
This disruption is forcing businesses to look at return on investment in R&D, and Calira says this will put increased pressure on LabOps teams to...
|
|
|
|
|
|
|
|
|
|
|
|
|
25.09.25 - 01:24
|
Moderna boss defends UK in drug-pricing row as he opens £150m Oxfordshire facility (The Guardian)
|
|
|
'We're here to invest,' says Darius Hughes as he calls comments by other pharma companies 'a little harsh'The UK boss of the US drugmaker Moderna, which shot to prominence with its Covid vaccine during the pandemic, has defended the country after it was labelled the “worst in Europe” for drug pricing.Darius Hughes spoke as he opened a £150m vaccine site in Oxfordshire, just days after MSD, AstraZeneca and Eli Lilly announced that they would ditch or pause planned UK investments amid a row over pricing between the pharmaceutical industry and the government. Continue reading......
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
